Natera, Inc.
Natera, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
4 of 4 strong
The short version
- Natera expects continued rapid growth in volumes and revenue, with Q1 2026 delivering 1 million units in a single quarter, a new milestone. - Natera anticipates continued strong revenue growth in 2026, having already reset the full-year revenue guide up by more than $120 million at the midpoint.
From Natera, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Natera expects continued rapid growth in volumes and revenue, with Q1 2026 delivering 1 million units in a single quarter, a new milestone.
- Oncology clinical units grew 55% year-over-year with record growth driven by colorectal and breast cancer indications plus new cancer types.
- Women’s health saw a very strong quarter with core Panorama and Horizon tests growing by 63,000 units quarter-over-quarter; Fetal Focus adoption is scaling towards 200,000 annualized test orders.
- Signatera volumes are expected to continue quarterly growth along the trailing 12-month average, with half of oncologists yet to adopt the test.
- Revenue guidance was raised by over $120 million at the midpoint, reflecting confidence in growth drivers.
- Expanding Medicare coverage and private payer opportunities are anticipated to further increase ASPs and revenue.
2 more points from Natera, Inc.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Natera, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Increased R&D spending by $50 million primarily to accelerate clinical trials, including the FIND early cancer detection (ECD) study, with enrollment expected to complete by Q3 2026.
- Opportunistic commercialization investments planned for the ECD assay launch, building commercial channels incrementally rather than large upfront hires, leveraging existing sales channels.
- Continued investment in medical education and specialized sales reps to drive growth in MRD products such as Signatera, focusing on new customer acquisition and market expansion.
2 more points from Natera, Inc.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Natera, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company processed nearly 250,000 clinical oncology units in the recent quarter, marking 55% growth over last year.
- Oncology tests are on a run rate exceeding 1 million MRD tests annually, with consistent quarterly growth in new patients.
- There is strong momentum with Signatera, showing steady adoption by oncologists (about 45-50% tried the test recently).
- The Fetal Focus product is approaching an annualized run rate of approximately 200,000 test orders.
- The firm anticipates a commercial launch in Japan for colorectal cancer (CRC) tests within 6 months, with good visibility on adoption post-approval.
2 more points from Natera, Inc.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Natera, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natera, Inc. Q2 FY26 results?
- Natera expects continued rapid growth in volumes and revenue, with Q1 2026 delivering 1 million units in a single quarter, a new milestone. - Natera anticipates continued strong revenue growth in 2026, having already reset the full-year revenue guide up by more than $120 million at the midpoint.
What is Natera, Inc. share price analysis?
Natera, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -531.3 with a market cap of $30,640. Investors should review the full earnings analysis for detailed insights.
Is Natera, Inc. planning capital expenditure?
- Increased R&D spending by $50 million primarily to accelerate clinical trials, including the FIND early cancer detection (ECD) study, with enrollment expected to complete by Q3 2026.
Keep Natera, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.